Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies

Table 2

Allele frequencies.

Gene	Reference SNP ID	Genotype	Our study (𝑛=103)	HWE; 𝑃	HapmapJPT^†; (𝑛=172)	𝑃	GeMDBJ^‡(MTHFR c.677C>T: 𝑛 = 2,375; MTHFR c.1298A>C: n = 1,428; SLCO1B1 c.521T>C: n = 1,427)	𝑃
MTHFR  c.677 C>T	rs1801133	CC	32		68		864
		CT	61		84		1123
		TT	10	0.049	20	0.442	388	0.885
MTHFR  c.1298 A>C	rs1801131	AA	68		112		952
		AC	31		56		435
		CC	4	0.633	4	0.924	41	0.765
SLCO1B1	rs11045879	TT	42		70		n.d.
		TC	43		74		n.d.
		CC	18	0.495	28	0.896	n.d.	n.d.
SLCO1B1  c.521 T>C	rs4149056	TT	73		138		1048
		TC	26		30		347
		CC	4	0.686	4	0.066	32	0.408

Difference of each allele frequency was calculated by  𝜒²  test.
†NCBI Hapmap JPT: database at National Center of Biotechnology Information (http://www.ncbi.nlm.nih.gov/).
The submitted SNP numbers to NCBI were ss65837366 for MTHFR C677T, ss76885974 for MTHFR A1298C, ss15510724 for SLCO1B1 rs11045879, and ss105439952 for SLCO1B1 T521C.
‡GeMDBJ: Genome Medicine Database of Japan (https://gemdbj.nibio.go.jp/dgdb/index.do).